Clinical impacts of hazardous alcohol use and obesity on the outcome of entecavir therapy in treatment-naïve patients with chronic hepatitis B infection

Chung, Won Gil; Kim, Hong Joo; Choe, Young Gil; Seok, Hyo Sun; Chon, Chang Wook; Cho, Yong Kyun; Kim, Byung Ik; Koh, Young Yool

doi:10.3350/cmh.2012.18.2.195

Cited by 13 publications

(14 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Seventy‐three studies examined the response to infection treatment in the obese vs. normal‐weight populations (Supporting Information http://onlinelibrary.wiley.com/doi/10.1111/obr.12320/suppinfo) . Fifteen of the studies did not find a statistically significant difference between the two groups.…”

Section: Resultsmentioning

confidence: 99%

Interaction of obesity and infections

2015

View full text Add to dashboard Cite

There is evidence that certain infections may induce obesity. Obese persons may also have more severe infections and have compromised response to therapies. The objective of this study is to review the available literature identifying infections that potentially contribute to greater body mass index (BMI) and differential responses of overweight and obese persons to infections. A systematic literature review of human studies examining associations between infections and weight gain, differential susceptibility, severity, and response to prevention and treatment of infection according to BMI status (January 1980-July 2014) was conducted. Three hundred and forty-three studies were eligible for inclusion. Evidence indicated that viral infection by human adenovirus Ad36 and antibiotic eradication of Helicobacter pylori were followed by weight gain. People who were overweight or obese had higher susceptibility to developing post-surgical infections, H1N1 influenza and periodontal disease. More severe infections tended to be present in people with a larger BMI. People with a higher BMI had a reduced response to vaccinations and antimicrobial drugs. Higher doses of antibiotics were more effective in obese patients. Infections may influence BMI, and BMI status may influence response to certain infections, as well as to preventive and treatment measures. These observations have potential clinical implications.

show abstract

Section: Resultsmentioning

confidence: 99%

Interaction of obesity and infections

2015

View full text Add to dashboard Cite

show abstract

“…Regarding alcohol consumption, Chung et al[44] reported that hazardous drinking (defined as a score of 8 or more on the Alcohol Use Disorders Identification Test) had no significant impact on the short-term outcome of 12 mo of entecavir treatment, measured as the rate of HBeAg seroconversion and HBV DNA negativity. Long-term treatment with lamivudine for a median duration of 32.4 mo can prevent progression to end-stage liver disease[45].…”

Section: Alcohol Consumption and Outcome Of Antiviral Treatmentmentioning

confidence: 99%

Hepatitis B virus infection and alcohol consumption

Iida‐Ueno¹,

Enomoto²,

Tamori³

et al. 2017

WJG

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, and the second most common cause of cancer deaths worldwide. The top three causes of HCC are hepatitis B virus (HBV), hepatitis C virus (HCV), and alcoholic liver disease. Owing to recent advances in direct-acting antiviral agents, HCV can now be eradicated in almost all patients. HBV infection and alcoholic liver disease are expected, therefore, to become the leading causes of HCC in the future. However, the association between alcohol consumption and chronic hepatitis B in the progression of liver disease is less well understood than with chronic hepatitis C. The mechanisms underlying the complex interaction between HBV and alcohol are not fully understood, and enhanced viral replication, increased oxidative stress and a weakened immune response could each play an important role in the development of HCC. It remains controversial whether HBV and alcohol synergistically increase the incidence of HCC. Herein, we review the currently available literature regarding the interaction of HBV infection and alcohol consumption on disease progression.

show abstract

“…Similar findings were reported for SVR in patients affected by chronic hepatitis B treated with Entecavir. 69 Nevertheless, alcohol consumption may lead to the overtreatment of patients with HBV infection. It was recently reported that elevated aminotransferase activity in only half of patients with HBV was due to an immune active chronic hepatitis B, whereas non-alcoholic fatty liver disease or alcohol consumption were considered other possible causes for enzyme elevation.…”

Section: Antivirals In Drinkersmentioning

confidence: 99%

Update on Alcohol and Viral Hepatitis

Gitto

Vitale

Villa

et al. 2014

JCTH

View full text Add to dashboard Cite

Alcohol consumption is often associated with viral hepatitis. Although alcohol is known to worsen viral liver disease, the interactions between alcohol and viral hepatitis are not fully understood. Molecular alterations in the liver due to alcohol and viral hepatitis include effects on viral replication, increased oxidative stress, cytotoxicity, and a weakened immune response. Clinically, alcohol enhances disease progression and favors induction of primitive liver neoplasm. The use of new antivirals for hepatitis C and well-established drugs for hepatitis B will determine how viral hepatitis can be controlled in a large percentage of these patients. However, alcohol-related liver disease continues to represent a barrier for access to antivirals, and it remains an unresolved health issue.

show abstract

Clinical impacts of hazardous alcohol use and obesity on the outcome of entecavir therapy in treatment-naïve patients with chronic hepatitis B infection

Cited by 13 publications

References 24 publications

Interaction of obesity and infections

Interaction of obesity and infections

Hepatitis B virus infection and alcohol consumption

Update on Alcohol and Viral Hepatitis

Contact Info

Product

Resources

About